Fact-checked by Grok 2 weeks ago

Primary tumor

A primary tumor is the original tumor in the body, representing the initial site where cancer cells first arise and proliferate. These malignant cells can invade adjacent tissues or spread via the bloodstream or lymphatic system to form secondary tumors, known as metastases, which retain the genetic and histological characteristics of the originating primary tumor.^[1] In oncology, the primary tumor is fundamental to cancer diagnosis, staging, and treatment planning, as it determines the cancer's origin and potential for dissemination. The TNM staging system, widely used internationally, categorizes the primary tumor based on its size, depth of invasion, and local extension (T category), alongside regional lymph node involvement (N) and distant metastasis (M), to assess disease progression and prognosis.^[2] Identifying and characterizing the primary tumor through imaging, biopsy, and histopathological analysis enables precise classification of the malignancy type, such as carcinoma, sarcoma, or lymphoma, which informs targeted therapies.^[3] Treatment of the primary tumor typically aims to achieve local control and prevent metastasis, with surgery serving as the cornerstone for resectable cases to remove the tumor and surrounding margins.^[4] Adjuvant therapies, including radiation to ablate residual cells and chemotherapy or targeted agents to address microscopic disease, are often employed following surgical intervention, particularly in cases with high-risk features like lymphovascular invasion.^[3] In metastatic settings, while systemic treatments address disseminated disease, local management of the primary tumor—such as through resection or ablation—may still confer survival benefits in select cancers, including breast^[5] and colorectal types.^[6]

Definition and Overview

Definition

A primary tumor is defined as the original mass of neoplastic cells that arises in a specific tissue or organ, marking the initial site of cancer development within the body.^[1] This tumor represents the first manifestation of malignancy at its point of origin, where abnormal cell growth begins due to uncontrolled proliferation.^[7] Primary tumors may remain localized to their site of origin or, through processes such as invasion and dissemination, give rise to secondary tumors known as metastases in distant organs.^[1] Cancers are conventionally named according to the tissue or organ of the primary tumor, such as lung cancer when the neoplasm originates in lung parenchyma or breast cancer from mammary gland tissue.^[8] In contrast, cancer of unknown primary (CUP) occurs when metastatic lesions are detected but the originating primary site cannot be identified despite thorough evaluation, accounting for approximately 2-5% of all cancer diagnoses.^[9]^[10] The concept of the primary tumor emerged in early 19th-century pathology, with foundational contributions from Rudolf Virchow, who advanced the understanding of tumors as cellular proliferations originating from normal tissues rather than humoral imbalances.^[11] Virchow's work in the 1850s, particularly his doctrine of cellular pathology, established the neoplastic mass at its anatomical site as the key to tumor classification and study.^[12]

Nomenclature and Classification

Primary tumors are named based on their tissue of origin and histological characteristics, with the term "primary" often prefixed to distinguish them from metastatic lesions arising elsewhere in the body. For epithelial-derived tumors, the nomenclature typically includes "carcinoma" for malignant forms, such as adenocarcinoma for those originating from glandular epithelium, while benign counterparts are termed adenomas or papillomas.^[13]^[14] Specific designations incorporate the organ or site, as in "primary hepatocellular carcinoma" for liver-origin epithelial malignancies. Mesenchymal tissue-derived tumors are classified as sarcomas when malignant, such as osteosarcoma from bone, whereas lymphoid-origin tumors are denoted as lymphomas.^[14]^[15] The World Health Organization (WHO) Classification of Tumours provides the authoritative framework for tumor nomenclature and categorization, now in its 5th edition across various organ systems, emphasizing integrated histological, genetic, and molecular features. This system, updated through 2025, incorporates molecular subtypes for precise identification, such as IDH-mutant astrocytomas in gliomas, and is supported by the International Classification of Diseases for Oncology (ICD-O-3). ICD-O-3 employs a five-digit morphology code where the first four digits specify the histological type (e.g., 8140 for adenocarcinoma) and the fifth digit indicates behavior: /0 for benign, /1 for borderline or uncertain, /2 for in situ, and /3 for malignant. The 2025 updates to solid tumor rules align with these WHO volumes, introducing new codes and terms to reflect evolving molecular insights.^[16]^[17]^[18] Primary tumors are broadly classified as benign or malignant based on their biological behavior, with malignant forms prioritized in oncology due to their invasive and metastatic potential. Benign primary tumors remain localized, exhibit slow growth, and lack the ability to invade surrounding tissues or spread distantly, such as leiomyomas from smooth muscle. In contrast, malignant primary tumors demonstrate uncontrolled proliferation, local invasion, and metastasis, exemplified by carcinomas, sarcomas, and lymphomas. This distinction is codified in ICD-O-3 behavior codes, guiding clinical management and prognosis.^[19]^[14]^[18] Special considerations apply to primary tumors of the central nervous system (CNS), classified under the WHO Classification of Tumours of the CNS, 5th edition (2021), with ongoing refinements through 2025. Gliomas, a major category of primary CNS tumors arising from glial cells, are stratified into adult-type diffuse gliomas, pediatric-type diffuse low- and high-grade gliomas, and circumscribed gliomas, integrating molecular markers like IDH and 1p/19q codeletion status. These are further graded from I to IV based on histological aggressiveness and molecular features, where grade I tumors are indolent and pilocytic, while grade IV, such as glioblastoma IDH-wildtype, exhibit rapid progression and poor prognosis. This layered approach facilitates targeted diagnostics and therapy.^[20]^[21]^[22]

Biological Characteristics

Microscopic and Histological Features

Primary tumors exhibit distinct microscopic and histological features that distinguish them from normal tissue, primarily through the presence of neoplastic cells displaying cellular atypia. These cells show marked variation in size and shape (pleomorphism), hyperchromatic and irregularly shaped nuclei, an increased nuclear-to-cytoplasmic ratio approaching 1:1, prominent nucleoli, and frequent mitotic figures, including atypical forms with abnormal chromosome arrangements.^[23]^[24] These characteristics reflect the loss of differentiation and uncontrolled proliferation inherent to malignancy at the primary site.^[25] The tumor microenvironment in primary tumors plays a crucial role in supporting neoplastic growth, featuring desmoplastic stroma composed of fibroblasts and extracellular matrix that provides structural support and facilitates tumor expansion. Angiogenesis is prominently induced within this microenvironment, driven by vascular endothelial growth factor (VEGF) expression from tumor cells, which promotes new blood vessel formation to meet the metabolic demands of the growing primary mass.^[26] Immune cell infiltration, including macrophages and lymphocytes, is often observed surrounding the primary tumor, contributing to an immunosuppressive niche that aids evasion of host defenses.^[27] Differentiation grades in primary tumors are assessed based on how closely neoplastic cells resemble their tissue of origin, with well-differentiated tumors showing organized architecture and cytologic features akin to normal cells, indicating lower aggressiveness. In contrast, poorly differentiated or anaplastic tumors display chaotic growth patterns, extreme pleomorphism, and minimal resemblance to normal tissue, correlating with higher malignancy potential. For instance, ductal carcinoma in situ (DCIS) in breast primaries often presents as well-differentiated, with uniform neoplastic cells confined to ducts and minimal atypia beyond nuclear enlargement and stratification.^[25]^[28] Tissue-specific immunohistochemistry aids in characterizing primary epithelial tumors, with markers such as cytokeratin 7 (CK7) and cytokeratin 20 (CK20) helping to identify the site of origin based on expression patterns; for example, CK7-positive/CK20-negative profiles are typical of upper gastrointestinal or lung primaries, while the reverse suggests colorectal origins.^[29]^[30]

Growth Patterns and Behavior

Primary tumors exhibit distinct patterns of local invasion, characterized by direct extension into surrounding tissues through breach of the basement membrane. This process often manifests as either a pushing border, where the tumor expands cohesively and displaces adjacent normal tissue while maintaining a well-defined interface, or an infiltrative pattern, involving irregular penetration with finger-like projections or dispersed cell clusters. For instance, prostate cancers frequently display a pushing border, allowing for relatively contained growth before deeper invasion.^[31] In contrast, pancreatic ductal adenocarcinomas typically show an infiltrative growth, with spiculated margins that facilitate early involvement of peripancreatic tissues and nerves.^[32] The kinetics of primary tumor growth generally follow an initial exponential phase, transitioning to slower expansion as described by the Gompertzian model. This model posits tumor volume V(t) as V(t) \approx V_0 e^{k(1 - e^{-bt})}, where V_0 is the initial volume, k represents the maximum growth rate, and b is the retardation factor influencing the slowdown. Derived from the imbalance between cell proliferation and loss rates—where net growth decelerates exponentially due to increasing cell death and nutrient limitations as the tumor enlarges—the Gompertzian function captures the observed sigmoidal curve of tumor progression in vivo, outperforming simpler exponential models for larger lesions.^[33] Certain primary tumors enter periods of dormancy, where growth halts due to equilibrium between proliferation and apoptosis, often preceding or following the angiogenic switch—a critical transition where pro-angiogenic factors like VEGF overpower inhibitors, enabling vascularization and renewed expansion. Spontaneous regression, though rare, occurs in some cases, such as neuroblastoma, where tumors may fully resolve without intervention through mechanisms including immune-mediated cytotoxicity or neurotrophin deprivation.^[34]^[35] Growth behavior varies significantly by tumor site and type, influencing clinical management. Basal cell carcinomas of the skin exemplify slow-growing primaries, with an average radial expansion of approximately 0.7 mm per month, rarely metastasizing due to limited invasive potential. Conversely, small cell lung cancers demonstrate aggressive kinetics, featuring short doubling times (typically 25-217 days) and high growth fractions (often 70-90%), leading to rapid local progression and early dissemination.^[36]^[37]^[38]

Pathogenesis

Cellular Origin and Development

The development of a primary tumor begins with the transformation of normal cells through a multi-step carcinogenesis process, classically divided into initiation, promotion, and progression stages.^[39] Initiation involves the acquisition of genetic damage, often from environmental carcinogens or endogenous errors, leading to irreversible mutations in a single cell that confer a proliferative advantage.^[40] This is followed by promotion, where these initiated cells undergo clonal expansion due to stimuli that enhance proliferation while inhibiting differentiation or apoptosis, resulting in preneoplastic lesions.^[41] Progression then occurs as additional alterations enable the lesion to invade surrounding tissue and acquire malignant potential, forming a detectable primary tumor.^[42] A well-characterized example of this model is the adenoma-carcinoma sequence in colorectal cancer, where normal colonic epithelium progresses through benign adenomas to invasive carcinoma over multiple accumulated changes.^[43] Initial APC gene inactivation leads to small adenomas during initiation, followed by KRAS mutations promoting growth into larger adenomas, and finally TP53 alterations driving progression to malignancy.^[44] This sequence illustrates how sequential hits build upon each other to foster tumor formation. During this developmental process, primary tumor cells acquire key hallmarks of cancer that underpin their autonomy and survival. Self-sufficiency in growth signals allows cells to proliferate without external mitogens, often through autocrine loops or receptor overexpression. Insensitivity to anti-growth signals enables evasion of tumor suppressors like RB, permitting unchecked division. Evasion of apoptosis is critical, frequently mediated by mutations in TP53, which impair DNA damage responses and allow survival of genetically unstable cells.^[45] Primary tumors arise from tissue-specific cellular origins, reflecting the differentiated state of the host tissue. Carcinomas, comprising over 90% of human cancers, originate from epithelial cells lining organs or glands, such as adenocarcinomas from glandular epithelium.^[14] In contrast, sarcomas derive from mesenchymal cells like fibroblasts or osteoblasts in connective tissues, leading to tumors such as fibrosarcomas.^[14] Both embryonic and adult stem cells play roles; cancer stem cells (CSCs), often arising from adult tissue stem cells with self-renewal capacity, initiate and sustain primary tumors, while rare embryonic-like stem cells may contribute in certain contexts by de-differentiating.^[46] The timeline from a single initiating mutated cell to a clinically detectable primary tumor typically spans 5-20 years, varying by tissue type and mutation rate. A detectable tumor often contains approximately 10^9 cells, requiring around 30 doublings from the initial clone, with slower-growing tumors like those in the colon taking longer than rapid ones in the pancreas.^[47]

Genetic and Molecular Mechanisms

The formation of primary tumors is driven by specific genetic alterations that confer proliferative advantages to cells at the tissue of origin. Oncogenes such as KRAS undergo gain-of-function mutations that constitutively activate downstream signaling, promoting uncontrolled cell growth; for instance, KRAS mutations occur in over 90% of pancreatic ductal adenocarcinoma primary tumors, where variants like G12D lock the protein in its GTP-bound active state, enhancing MAPK pathway flux.^[48] In contrast, tumor suppressor genes like BRCA1 and BRCA2 experience loss-of-function mutations or deletions, impairing DNA repair and leading to genomic instability; these alterations are prevalent in 5-10% of breast primary cancers and up to 15% of ovarian primary cancers, increasing susceptibility to double-strand breaks and tumorigenesis.^[49] Similarly, TP53 loss-of-function mutations, found in over 50% of diverse primary tumors, disable cell cycle checkpoints and apoptosis, facilitating the survival of damaged cells.^[50] Genomic instability is a hallmark of primary tumor development, manifesting as chromosomal aberrations that amplify oncogenic signals. Aneuploidy and chromosomal instability (CIN) arise frequently following TP53 inactivation, resulting in copy number alterations (CNAs) that drive tumor evolution; for example, CNAs are detected in early stages of esophageal adenocarcinoma primaries progressing from Barrett's esophagus.^[50] Microsatellite instability (MSI-high) occurs in 10-15% of colorectal primary tumors associated with Lynch syndrome, caused by germline mutations in mismatch repair genes like MLH1, leading to hypermutation and immune evasion at the primary site.^[51] Epigenetic modifications further sustain primary tumor maintenance by silencing protective genes without altering DNA sequence. Promoter hypermethylation of tumor suppressors, such as MGMT in gliomas, inactivates DNA repair mechanisms, rendering primary glioblastoma cells more prone to mutagenesis; this change is observed in approximately 40-50% of primary gliomas and correlates with enhanced tumor initiation.^[52] Histone modifications, including deacetylation and methylation, also contribute by compacting chromatin around genes like CDKN2A in various primaries, promoting dedifferentiation and proliferation.^[50] Dysregulated signaling pathways integrate these genetic changes to orchestrate primary tumor growth. The PI3K/AKT/mTOR pathway is hyperactivated in many primaries through gain-of-function mutations in PIK3CA, as seen in 25-30% of breast primary cancers, driving anabolic metabolism and survival; pathway flux can be modeled as the rate of AKT activation ≈ k \times [ligand] / (1 + K_i/[inhibitor]), where k is the catalytic rate and K_i reflects inhibition sensitivity, illustrating competitive regulation by PTEN loss.^[53] In colorectal primaries, the Wnt/β-catenin pathway is aberrantly activated by loss-of-function mutations in APC (in ~80% of cases), stabilizing β-catenin to transcriptionally induce c-MYC and cyclin D1, thereby fueling stem-like proliferation at the intestinal origin site.^[54]

Clinical Aspects

Symptoms and Presentation

Primary tumors often present with symptoms that vary widely depending on their anatomical location, size, and rate of growth, making early detection challenging as many cases remain asymptomatic until advanced stages. Localized symptoms arise from direct effects such as mass effect, obstruction, or tissue invasion, while systemic signs may reflect the body's response to the malignancy. These manifestations prompt clinical evaluation, often leading to diagnostic investigations like imaging or biopsy.^[55] Site-specific symptoms are hallmark features that guide initial suspicion of a primary tumor. In breast primaries, patients commonly report a painless lump or thickening in the breast or underarm area, sometimes accompanied by changes in breast size, shape, nipple inversion, or skin dimpling resembling peau d'orange.^[56] For lung primaries, particularly non-small cell types, hemoptysis (coughing up blood), persistent cough, chest pain, shortness of breath, or hoarseness may occur due to bronchial irritation or obstruction.^[57] Pancreatic primaries frequently manifest with jaundice (yellowing of the skin and eyes), dark urine, light-colored stools, and upper abdominal or back pain from bile duct compression or local invasion.^[58] In colorectal primaries, early signs include changes in bowel habits such as diarrhea, constipation, or narrower stools, along with rectal bleeding or abdominal cramps from luminal narrowing.^[59] Paraneoplastic syndromes represent remote effects of primary tumors mediated by humoral factors or immune responses, occurring in up to 10-20% of cases and often preceding local symptoms. For instance, hypercalcemia associated with squamous cell carcinoma primaries (e.g., lung or head and neck) results from ectopic secretion of parathyroid hormone-related peptide, leading to symptoms like fatigue, nausea, confusion, and polyuria.^[60] General signs tied to the primary tumor's location and systemic impact include unexplained weight loss, fatigue, and anemia of chronic disease, which may arise from cytokine release or nutritional deficits; in gastrointestinal primaries, these can compound with localized obstructive effects.^[61] Many primary tumors are detected incidentally in asymptomatic individuals through routine screening, highlighting the role of early detection programs in identifying curable cases. For prostate primaries, elevated prostate-specific antigen (PSA) levels in blood tests can signal occult tumors without urinary symptoms or palpable masses, prompting further evaluation in otherwise healthy men.^[62] Similarly, mammographic detection of non-palpable breast lesions or computed tomography findings of lung nodules in low-dose screening represent common asymptomatic discoveries. As primary tumors progress, symptoms evolve from subtle localized cues to severe obstructive or systemic complications, underscoring the importance of timely intervention. In colorectal primaries, initial bowel habit changes may advance to complete obstruction, causing acute abdominal pain, distension, vomiting, and constipation over weeks to months as the tumor enlarges and invades surrounding structures.^[59] This timeline varies by site; for example, slow-growing breast tumors might remain indolent for years with minimal symptoms, whereas aggressive pancreatic lesions can lead to cachexia and biliary obstruction within months.^[61]

Epidemiology and Risk Factors

Primary tumors, representing the initial sites of malignant growth, contribute to the global burden of cancer, with an estimated 18.7 million new cases diagnosed worldwide in 2022, excluding non-melanoma skin cancers.^[63] Among these, lung cancer accounted for approximately 2.5 million cases, breast cancer for 2.3 million, and colorectal cancer for 1.9 million, highlighting the predominance of epithelial-origin primaries in incidence statistics. Site-specific variations are notable; for instance, liver cancer primaries exhibit higher rates in Asia and Africa, with nearly 50% of global cases occurring in Eastern Asia, largely attributable to endemic hepatitis B virus prevalence. Demographic patterns of primary tumor occurrence reveal strong associations with age, sex, and geography. The majority of primary cancers develop in individuals over 50 years, with incidence rates rising exponentially after age 65 due to cumulative cellular damage and reduced immune surveillance. Sex-based disparities are evident, such as prostate cancer primaries affecting males at rates 20 times higher than females globally, while breast cancer primaries are nearly exclusive to females. Geographically, cervical cancer primaries show elevated incidence in low- and middle-income countries, with age-standardized rates exceeding 20 per 100,000 in sub-Saharan Africa and South Asia, compared to under 10 per 100,000 in high-income regions. Key risk factors for primary tumor development encompass environmental, infectious, and genetic elements. Environmental exposures, including tobacco smoking, are responsible for about 20-30% of cancer cases, particularly lung and bladder primaries, where smokers face a 15-30 times higher risk than non-smokers. Ultraviolet radiation from sun exposure significantly elevates skin melanoma primary risk, with fair-skinned populations in sunny regions showing incidence rates up to 50 per 100,000. Infectious agents contribute to 15-20% of global malignancies, such as human papillomavirus (HPV) causing over 90% of cervical primaries and hepatitis B virus (HBV) linked to 50% of liver primaries. Genetic predispositions, though rarer, include hereditary syndromes like Li-Fraumeni syndrome, which confers a lifetime cancer risk exceeding 90% due to germline TP53 mutations. Recent trends indicate shifts in primary tumor epidemiology through 2025, influenced by lifestyle and preventive measures. Smoking-related primaries, such as lung cancer, have seen declining incidence in high-income countries, with U.S. rates dropping 2-3% annually since 2010 due to reduced tobacco use.^[64] Conversely, obesity-associated primaries are rising, with endometrial cancer incidence increasing 1-2% per year globally, projected to affect an additional 10-15% more cases by 2025 amid escalating obesity prevalence.^[65] Overall, global projections indicate continued increases in new primary cancer cases driven by population aging and socioeconomic transitions.^[66]

Diagnosis

Imaging and Detection Methods

Imaging and detection of primary tumors primarily rely on non-invasive modalities that visualize anatomical structures, tissue characteristics, and metabolic activity to identify suspicious lesions. Computed tomography (CT) and X-ray are commonly used for detecting chest masses, such as in lung cancer, providing detailed cross-sectional images that reveal tumor size, location, and density.^[67] Magnetic resonance imaging (MRI) excels in evaluating brain and soft tissue tumors due to its superior soft tissue contrast and lack of ionizing radiation, allowing for precise delineation of tumor boundaries without the artifacts seen in CT.^[68] Ultrasound serves as a first-line tool for superficial primary tumors, including those in the thyroid, offering real-time imaging with high resolution for accessible sites and guiding subsequent interventions.^[69] Positron emission tomography-computed tomography (PET-CT) integrates metabolic data with anatomical imaging, where standardized uptake values (SUV) greater than 2.5 often indicate malignant primary tumors by highlighting increased glucose metabolism in cancerous cells.^[70] Screening programs employing these modalities have demonstrated significant benefits in early primary tumor detection for high-incidence cancers. Screening mammography for average-risk women is recommended starting at age 40-45 by major organizations, with the American Cancer Society suggesting annual screening from age 45 (optional from 40-44) and the U.S. Preventive Services Task Force recommending biennial screening from age 40 to 74, reducing breast cancer mortality by 20-40% through the identification of non-palpable primaries, with randomized trials showing a 41% risk reduction within 10 years of participation.^[71] For colorectal cancer, colonoscopy every 10 years from age 45 is the gold standard for average-risk individuals, enabling the detection and removal of precancerous polyps while directly visualizing primary lesions in the colon and rectum.^[72] These programs emphasize age-appropriate initiation to maximize mortality reduction while balancing procedural risks, with endorsements varying by organization and cancer type (e.g., both the American Cancer Society and U.S. Preventive Services Task Force support colorectal screening from age 45).^[73] As of 2025, emerging technologies are enhancing the sensitivity and specificity of primary tumor detection. Artificial intelligence (AI), particularly deep learning algorithms integrated into imaging workflows, improves lesion detection in modalities like MRI and CT, achieving sensitivities exceeding 95% for brain tumors in validation studies by automating feature extraction and reducing interpretive variability.^[74] Liquid biopsies, analyzing circulating tumor DNA (ctDNA) shed from primary tumors into the bloodstream, offer a non-invasive complementary approach for early detection, with advances in next-generation sequencing enabling ctDNA identification at low concentrations for cancers like colorectal and breast primaries.^[75] These innovations, including AI-enhanced PET-CT for metabolic profiling, are increasingly adopted in clinical trials to refine risk stratification and personalize screening.^[76] Despite their efficacy, imaging and detection methods face notable limitations that can impact clinical utility. False positives, arising from benign conditions mimicking tumor characteristics, lead to unnecessary follow-up procedures and patient anxiety, with mammography false-positive rates reaching 10-15% over multiple screenings.^[77] False negatives may occur in dense tissues or small lesions, potentially delaying diagnosis, as seen in up to 20% of early-stage breast cancers missed on initial mammograms.^[78] Additionally, ionizing radiation exposure from CT and PET-CT poses a cumulative cancer risk, estimated at 1 in 2,000 for a single abdominal CT scan, necessitating judicious use especially in screening contexts.^[79] These challenges underscore the need for multimodal approaches and ongoing technological refinements to optimize detection accuracy.

Biopsy and Pathological Confirmation

Confirmation of a primary tumor typically requires a biopsy to obtain tissue or cells for pathological analysis, distinguishing it from non-invasive imaging methods by providing definitive histological evidence.^[80] Various biopsy techniques are employed depending on the tumor's location, size, and accessibility, with the goal of minimizing invasiveness while ensuring adequate sampling.^[81] Fine-needle aspiration (FNA) involves using a thin needle to extract cells for cytological examination, suitable for superficial or accessible lesions like thyroid nodules, though it may yield insufficient material for detailed histology.^[80] Core needle biopsy employs a larger needle to obtain cylindrical tissue cores, providing histological architecture and preferred for solid primary tumors such as breast or lung masses, often guided by imaging to target suspicious areas.^[80] For small, discrete lesions, excisional biopsy removes the entire tumor, allowing comprehensive evaluation but reserved for cases where complete resection is feasible without compromising larger structures.^[82] Endoscopic biopsy, using flexible scopes, is standard for gastrointestinal primaries, enabling direct visualization and sampling of mucosal abnormalities.^[80] Pathological evaluation begins with hematoxylin and eosin (H&E) staining, the cornerstone for visualizing cellular morphology, nuclear details, and tissue architecture to confirm malignancy and identify the tumor's primary origin.^[83] Special histochemical stains, such as periodic acid-Schiff (PAS), detect mucin production in adenocarcinomas, aiding differentiation of tumor types by highlighting polysaccharides in glandular structures.^[84] Molecular testing complements routine histology; for instance, fluorescence in situ hybridization (FISH) assesses HER2 gene amplification in breast primaries, guiding targeted therapies by quantifying copy numbers in tumor nuclei.^[85] Tumor grading systems quantify aggressiveness based on histological features, influencing prognosis and management. The Gleason score for prostate primaries ranges from 2 to 10, summing the dominant and secondary architectural patterns (each graded 1-5), with scores of 6 indicating low-grade disease and 8-10 high-grade.^[86] In breast cancer, the Nottingham histologic score (1-3 overall) evaluates tubule formation, nuclear pleomorphism, and mitotic count, where grade 3 signifies poorly differentiated, aggressive tumors.^[87] Challenges in biopsy and pathological confirmation include sampling errors, which can occur in up to 41% of cases due to tumor heterogeneity, potentially leading to under- or overestimation of grade or type, particularly in pelvic tumors.^[88] To mitigate these, multidisciplinary tumor boards convene pathologists, oncologists, radiologists, and surgeons for integrated review of biopsy results, imaging, and clinical data, ensuring accurate interpretation and reducing diagnostic discrepancies.^[89]

Treatment and Management

Surgical and Local Therapies

Surgical resection represents a cornerstone of curative intent treatment for localized primary tumors, aiming to remove the entire tumor mass along with a margin of surrounding healthy tissue to minimize the risk of local recurrence. In early-stage breast cancer, lumpectomy—also known as breast-conserving surgery—involves excision of the primary tumor and a 1-2 cm margin of normal tissue, preserving the breast while achieving oncologic control comparable to mastectomy when followed by radiation.^[90] For pancreatic adenocarcinoma confined to the head of the pancreas, the Whipple procedure (pancreaticoduodenectomy) resects the tumor, duodenum, part of the pancreas, and nearby structures, offering potential cure in resectable cases with 5-year survival rates of 18-24% for complete resections.^[91] The success of resection is classified by margin status: R0 denotes complete removal with no microscopic residual tumor (negative margins), R1 indicates microscopic involvement at the margins, and R2 signifies gross residual disease, with R0 achieving the best local control rates across tumor types.^[92] Surgical planning is informed by preoperative staging to determine resectability.^[90] Radiation therapy targets the primary tumor site to induce cell death through ionizing radiation, primarily by causing DNA double-strand breaks that overwhelm cellular repair mechanisms, leading to apoptosis or mitotic catastrophe. External beam radiation therapy (EBRT) delivers fractionated doses, typically 45-50 Gy over 5-6 weeks in 1.8-2 Gy daily increments, to the tumor bed and regional nodes for cancers such as breast or lung primaries, balancing efficacy with toxicity to adjacent organs.^[90]^[93] Brachytherapy, an internal form of radiation, places radioactive sources directly into or near the tumor, such as in cervical cancer where high-dose-rate applicators deliver 20-30 Gy to the primary site following EBRT, enabling higher doses to the tumor while sparing distant tissues.^[94] Ablative techniques provide minimally invasive options for small primary tumors unsuitable for or as alternatives to surgery, using thermal energy to destroy tumor cells while preserving surrounding structures. Radiofrequency ablation (RFA) applies high-frequency alternating current via needle electrodes to heat tissue to 60-100°C, coagulating proteins and causing necrosis; it is particularly effective for small renal cell carcinomas (<3 cm), achieving complete response rates of 90-100% at 1 year with low complication rates.^[95] Cryotherapy, or cryoablation, freezes tumor tissue to -20°C or lower using probes to form ice balls that disrupt cell membranes and induce ischemia, commonly applied percutaneously for small renal primaries with technical success rates exceeding 95% and minimal impact on renal function.^[96] As of 2025, proton therapy has advanced as a precise radiation modality for pediatric primary tumors, leveraging the Bragg peak to deposit energy directly at the tumor depth while minimizing exit dose to healthy tissues, thus reducing long-term sequelae such as secondary malignancies and neurocognitive deficits. In children with brain or spinal primaries, pencil beam scanning proton therapy spares critical structures like the hippocampus and heart, with studies showing 20-50% lower integral dose to normal tissues compared to photon therapy and equivalent local control rates of 80-90% at 5 years.^[97]^[98]

Systemic Therapies and Prognosis

Systemic therapies play a crucial role in managing primary tumors by targeting cancer cells throughout the body, often used in adjuvant or neoadjuvant settings to complement local treatments and improve outcomes. Chemotherapy remains a cornerstone, employing agents that interfere with DNA replication and cell division. Alkylating agents, such as cyclophosphamide, are widely used in regimens for breast and ovarian primaries, forming part of combination therapies like CMF (cyclophosphamide, methotrexate, and fluorouracil) that have demonstrated reduced recurrence risk in early-stage disease.^[99]^[100] Antimetabolites, including 5-fluorouracil (5-FU), are particularly effective for gastrointestinal primaries, often combined with oxaliplatin or irinotecan in protocols like FOLFOX, which in the adjuvant setting for stage III colorectal cancer has improved 3-year disease-free survival to 78.2% compared to 72.9% with 5-FU plus leucovorin alone, as shown in the MOSAIC trial.^[101] Targeted therapies and immunotherapy have transformed treatment for specific primary tumor subtypes by exploiting molecular vulnerabilities. Tyrosine kinase inhibitors (TKIs) like imatinib target BCR-ABL fusion proteins in chronic myeloid leukemia (CML) primaries, achieving complete cytogenetic responses in over 80% of chronic-phase patients and markedly improving long-term survival.^[102] For solid tumors with microsatellite instability-high (MSI-H) features, such as certain colorectal or endometrial primaries, PD-1 inhibitors like pembrolizumab yield objective response rates (ORR) of approximately 40%, with durable responses in advanced settings due to enhanced T-cell activation against tumor neoantigens.^[103] Prognosis for primary tumors is influenced by multiple factors, including TNM staging and molecular biomarkers, which guide therapeutic decisions and predict survival. In breast cancer, stage I disease confers a 5-year overall survival rate of about 90-99%, contrasting sharply with stage IV at around 30%, reflecting the impact of tumor size, nodal involvement, and metastasis on disease progression.^[104] The Ki-67 proliferation index serves as a key biomarker, with levels above 25-30% indicating higher tumor aggressiveness and poorer outcomes, such as reduced disease-free survival in triple-negative breast cancer subtypes.^[105]^[106] By 2025, advances in systemic therapies continue to enhance prognosis, particularly for hematologic primaries. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough for B-cell malignancies like diffuse large B-cell lymphoma, with approved products achieving complete remission rates of 40-50% in refractory cases through engineered T-cells targeting CD19.^[107] Overall cancer mortality has declined by 34% since 1991, averting approximately 4.5 million deaths through integrated systemic approaches, early detection, and reduced smoking prevalence, as reported by the American Cancer Society.^[108]

Distinctions from Metastatic Tumors

Key Biological Differences

Primary tumors originate at the site of initial oncogenic transformation and typically retain a high degree of fidelity to their tissue of origin through the expression of specific molecular markers, such as prostate-specific antigen (PSA) in prostate primaries, which is often diminished or lost in corresponding metastases due to epigenetic silencing or clonal selection during dissemination.^[109] This retention of origin-specific markers in primaries contrasts with metastases, where dedifferentiation can lead to reduced expression of lineage-defining genes, facilitating adaptation to secondary sites but complicating diagnostic identification.^[110] In general, primary tumors exhibit greater intratumor heterogeneity compared to metastases, reflecting a diverse population of subclones at the onset of tumorigenesis, whereas metastatic lesions show increased clonality and reduced heterogeneity due to selective bottlenecks during dissemination and colonization.^[111]^[112] The tumor microenvironment (TME) of primary tumors features native stromal and immune interactions tailored to the organ of origin, including supportive extracellular matrix and resident immune cells that initially constrain or promote early growth in a localized context.^[113] In contrast, metastatic tumors adapt to foreign host environments at distant sites, often remodeling the TME to favor survival and proliferation, as exemplified by the "seed-and-soil" hypothesis, which posits that compatible metastatic niches—such as pre-conditioned stromal beds in the lung or liver—enhance colonization efficiency beyond what is seen in the primary site's native milieu.^[114] This adaptation in metastases involves recruitment of distinct immune subsets, like fewer tumor-infiltrating lymphocytes (TILs) in brain metastases compared to primaries, underscoring site-specific immune evasion strategies not prominent in the original tumor.^[115]^[116] Genetically, primary tumors harbor the initial driver mutations that initiate oncogenesis, such as early alterations in TP53 or CDKN2A, establishing the foundational clonal architecture without the extensive parallel evolution seen in later stages.^[112] Metastases, however, undergo further genetic evolution through clonal selection, acquiring additional resistance mutations—often in therapeutically enriched drivers like those conferring chemotherapy resistance—resulting in a moderate increase in tumor mutation burden and structural variants compared to primaries.^[111] This evolutionary divergence is evident in pan-cancer analyses, where metastatic genomes display conserved karyotypes from primaries but with amplified aneuploidy or APOBEC-related signatures in specific types, such as breast or prostate cancers, driving aggressive progression.^[112]^[110] Behaviorally, primary tumors often exhibit slower initial growth rates, confined by the native organ's architectural constraints and immune surveillance, with limited vascular mimicry that relies more on conventional angiogenesis for nutrient supply.^[117] Metastatic tumors, selected for enhanced invasiveness, demonstrate accelerated growth potential in permissive soils and greater propensity for vascular mimicry, where tumor cells form fluid-conducting channels independent of endothelial cells, promoting rapid expansion and further dissemination in secondary sites.^[118] This behavioral shift highlights how primaries prioritize localized expansion, while metastases evolve mechanisms for efficient colonization and survival in heterogeneous environments.^[119]

Therapeutic Implications

The distinction between primary and metastatic tumors fundamentally shapes therapeutic strategies, emphasizing localized interventions for primaries to achieve cure while relying on systemic approaches for disseminated disease. For resectable primary tumors, surgical resection is the cornerstone, often yielding high cure rates when confined to the original site. In localized colorectal cancer, for example, complete surgical removal combined with adjuvant therapy results in a 5-year overall survival rate of approximately 91%.^[120] In contrast, occult primaries in cancer of unknown primary (CUP) necessitate empiric systemic therapy, as local control is infeasible without identifying the origin.^[121] Challenges in CUP management include limited efficacy of standard treatments, with platinum-based chemotherapy regimens achieving partial or complete responses in about 35% of patients following initial cycles. Median progression-free survival with such empiric approaches is around 4.4 months, underscoring the need for refined diagnostics. Advances in genomic profiling as of 2025 have enhanced tissue-of-origin prediction accuracy to 80-90%, allowing for more precise site-specific or molecularly guided therapies that improve progression-free survival to 6.1 months in responsive subsets.^[122]^[9] To mitigate the risk of metastasis, neoadjuvant therapies target primary tumors to induce shrinkage before dissemination occurs. In breast cancer, neoadjuvant chemotherapy leads to measurable tumor reduction in roughly 95% of cases, with an average shrinkage of 49%, facilitating downstaging and increasing eligibility for breast-conserving surgery.^[123] Prognostic outcomes diverge sharply based on this primary-metastatic divide, with localized disease offering far superior survival compared to advanced stages. For colorectal cancer, the 5-year overall survival reaches 91% for localized primaries but drops to 15% in metastatic settings, highlighting the critical window for early intervention.^[120]

References

[1]
Definition of primary tumor - NCI Dictionary of Cancer Terms
A term used to describe the original, or first, tumor in the body. Cancer cells from a primary tumor may spread to other parts of the body and form new, or ...Missing: oncology | Show results with:oncology
[2]
Cancer Staging - NCI
Oct 14, 2022 · The T refers to the size and extent of the main tumor. The main tumor is usually called the primary tumor. · The N refers to the number of nearby ...Diagnosis and Staging · Diagnosis and Staging Research · Symptoms of Cancer
[3]
TNM Classification - StatPearls - NCBI Bookshelf - NIH
The TNM Classification is a system for classifying a malignancy. It is primarily used in solid tumors and can assist in prognostic cancer staging.
[4]
Cancer treatment - Mayo Clinic
Jul 26, 2024 · The most common primary treatment for most cancers is surgery. Some cancers may respond very well to radiation therapy or chemotherapy. If so, ...Why It's Done · How You Prepare · What You Can Expect
[5]
Surgical treatment of the primary tumour improves the overall ... - PMC
It was concluded that surgery of the primary tumour in stage IV breast cancer appears to offer a survival benefit in metastatic patients.Results · Table I · Meta-Analysis For Os
[6]
Cancer Overview | The University of Kansas Cancer Center
What are primary tumors? The original tumor is called the primary tumor. Its cells can break off and travel through the body and begin forming additional tumors ...
[7]
Carcinoma of unknown primary - Symptoms and causes - Mayo Clinic
Dec 4, 2024 · The place where a cancer started growing is called the primary cancer. Sometimes health professionals first detect a cancer when it spreads.
[8]
Cancer of Unknown Primary Site: A New Era of Practice-Changing ...
Nov 12, 2024 · In the United States, about 2%-3% annually with metastasis have CUP and with improved diagnostic technology to localize anatomical primaries, ...
[9]
The currently declining incidence of cancer of unknown primary
CUP accounted for 3-5% of cancers in the historical series but its incidence seems to decline in the recent publications. This paper reviews the published ...
[10]
Two Hundred Years of Cancer Research
May 30, 2012 · A few astute observers were ahead of their time, including Rudolf Virchow, who with the benefit of a microscope deduced the cellular origin ...
[11]
[PDF] Rudolf Virchow - Semantic Scholar
Aug 29, 2024 · Virchow differentiated the origin of cancer cells from normal cells and suggested that dormant cell activation gives rise to cancer. He ...
[12]
Tumor Nomenclature - Oncology - Medbullets Step 1
Feb 9, 2019 · Tumor Nomenclature ; Cell type. Benign. Malignant ; Epithelium. Adenoma, papilloma. Adenocarcinoma and papillary carcinoma ; Melanocyte. Nevus.
[13]
Cancer Classification - SEER Training Modules
Cancers are classified in two ways: by the type of tissue in which the cancer originates (histological type) and by primary site, or the location in the body ...
[14]
[PDF] 2. Cancer NOMENCLATURE HYSTOPATHOLOGY-STUDENTS
① Carcinoma: Malignant tumors of epithelial cell origin. The name of organ and derived tissue/ cell + carcinoma. e. g. adenocarcinoma of thyroid. More details:.
[15]
WHO Classification of Tumours - IARC Publications
The WHO Classification of Tumours is a series of authoritative and concise reference books, previously based on histological and molecular classification ...Head and Neck Tumours · Haematolymphoid Tumours · Breast Tumours
[16]
[PDF] Solid Tumor Rules 2025 Update - SEER
Jan 1, 2018 · The Solid Tumor Rules are revised annually to reflect new terminology, ICD-O codes, and other changes needed to keep in step with current ...
[17]
International Classification of Diseases for Oncology, 3rd Edition ...
The morphology axis provides five-digit codes ranging from M-8000/0 to M-9989/3. The first four digits indicate the specific histological term. The fifth digit ...
[18]
Benign vs Malignant Tumors | Oncology - JAMA Network
Benign tumors are those that stay in their primary location without invading other sites of the body. They do not spread to local structures or to distant parts ...
[19]
WHO classification of CNS tumors | Radiology Reference Article
The WHO classification of CNS tumors (5th edition) is the most widely accepted for classifying CNS tumors. It was published in 2021.
[20]
The 2021 WHO Classification of Tumors of the Central Nervous ...
Jun 29, 2021 · The fifth edition of the WHO Classification of Tumours uses the HUGO Gene Nomenclature Committee (HGNC) system for gene symbols and gene names ...
[21]
What's new in neuropathology 2024: CNS WHO 5th edition updates
PEDIATRIC-TYPE DIFFUSE HIGH-GRADE GLIOMAS. • Each tumor type demonstrates diffusely infiltrative growth, high-grade morphologic features, and variably ...
[22]
Anaplasia - an overview | ScienceDirect Topics
Anaplastic cells generally have hyperchromatic nuclei, prominent nucleoli, and a nucleus to cytoplasm size ratio that approaches 1:1.Carcinogenesis · Qualitative--Metaplasia... · Qualitative Cell...
[23]
Diagnostic cellular abnormalities in neoplastic and non ... - NIH
Abnormal mitotic figures, pleomorphic parakeratosis, crowding and irregular nuclei were among the most specific features for malignancy (specificity 94–100%).Table 2 · Discussion · Fig. 4
[24]
Tumor Grade - NCI - National Cancer Institute
Aug 1, 2022 · Tumor grade describes how normal or abnormal cancer cells look under a microscope. The more normal the cells look, the less aggressive the cancer.
[25]
The role of microenvironment in tumor angiogenesis
Sep 30, 2020 · In this review, we have discussed the regulatory role of the microenvironment in tumor angiogenesis. High expression of angiogenic factors and ...
[26]
Direct and indirect regulation of the tumor immune ... - PubMed Central
Apr 25, 2022 · In this review, we discuss the direct and indirect effects of VEGF on the immunosuppressive tumor microenvironment with particular focus on the ...
[27]
Ductal carcinoma in situ (DCIS): pathological features, differential ...
May 3, 2010 · Factors that should be included in a histological report of a case of DCIS include cytonuclear grade, presence or absence of necrosis, size of ...
[28]
Cytokeratin 7 and 20 as immunohistochemical markers in ... - PubMed
Cytokeratin (CK)7 and CK20, the low molecular weight cytokeratins, have been found to have a benefit in the differential diagnosis of some epithelial neoplasms.
[29]
The value of CDX2 and cytokeratins 7 and 20 expression in ...
Jan 23, 2012 · The cytokeratins most often used are CK7 and CK20 [7–10]. CK7 is found in the glandular epithelium and epithelial tumors of lung, ovary ...
[30]
Characterization of cytoplasmic cyclin D1 as a marker of ... - NIH
Apr 20, 2016 · Pushing border invasion. Characterized by a cohesive tumour growth ... Several specific types of tumor invasion, depending of tumor site, were ...
[31]
The radiomorphological appearance of the invasive margin in ... - NIH
May 29, 2024 · Pancreatic cancer (PDAC) is characterized by infiltrative, spiculated tumor growth into the surrounding non-neoplastic tissue.
[32]
Classical Mathematical Models for Description and Prediction ... - NIH
Abstract. Despite internal complexity, tumor growth kinetics follow relatively simple laws that can be expressed as mathematical models.
[33]
Tumor dormancy: potential therapeutic target in tumor recurrence ...
Oct 16, 2013 · The transition from a pre-vascular tumor to a highly vascularized and progressively growing tumor is known as the “angiogenic switch” [26].
[34]
Spontaneous regression of neuroblastoma - PMC - PubMed Central
Jan 5, 2018 · There is evidence to support several possible mechanisms of spontaneous regression in neuroblastomas: (1) neurotrophin deprivation, (2) loss of ...
[35]
Growth rate of basal cell carcinoma: a meta-analysis and systematic ...
The presented analysis shows that BCC is generally a slow-growing tumour, with a mean growth rate of about 0.7 mm/month.
[36]
Small Cell Lung Cancer: Will Recent Progress Lead to Improved ...
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth ...
[37]
7.2: Carcinogenesis - Medicine LibreTexts
Jul 14, 2025 · The transformation of a normal cell into a cancer cell is a multi-step process that involves initiation, promotion, progression and finally malignancy.
[38]
Mechanisms for the Initiation and Promotion of Carcinogenesis
Carcinogenesis in humans is a multistage process, and the two major stages have been designated initiation and promotion.
[39]
An evolutionary model for initiation, promotion, and progression in ...
Jan 7, 2008 · Human carcinogenesis is a multistep process in which epithelial cells progress through a series of premalignant phenotypes until an invasive ...
[40]
An evolutionary model for initiation, promotion, and progression in ...
Human carcinogenesis is a multistep process in which epithelial cells progress through a series of premalignant phenotypes until an invasive cancer emerges.Missing: multi- | Show results with:multi-
[41]
The colorectal adenoma-carcinoma sequence - PubMed
It is widely accepted that the adenoma-carcinoma sequence represents the process by which most, if not all, colorectal cancers arise.
[42]
Pathways of Colorectal Carcinogenesis - PMC - NIH
Adenoma–Carcinoma Sequence. Most colorectal tumors arise from pre-cancerous polyps that are broadly categorized as either traditional tubular adenomas or ...
[43]
Cancer Stem Cells - PMC - NIH
Sep 2, 2012 · Cancer Stem Cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity
[44]
Genetic Progression and the Waiting Time to Cancer - PMC - NIH
Each driver mutation thereby allows the mutant cell to go through a wave of clonal expansion. Along with drivers, passenger mutations, which do not confer any ...Missing: timeline | Show results with:timeline
[45]
KRAS mutation in Pancreatic Cancer - PMC - PubMed Central
This review will present an updated summary of our understanding of mutant KRAS function in pancreatic cancer and discuss therapeutic strategies.
[46]
BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet
Jul 19, 2024 · The risks of developing breast and ovarian cancer are markedly increased in people who inherit a harmful change in BRCA1 or BRCA2 (1, 3–7).
[47]
Tumor initiation and early tumorigenesis: molecular mechanisms ...
Abstract. Tumorigenesis is a multistep process, with oncogenic mutations in a normal cell conferring clonal advantage as the initial event.
[48]
Current Hypotheses on How Microsatellite Instability Leads to ...
High levels of microsatellite instability (MSI-high) are a cardinal feature of colorectal tumors from patients with Lynch Syndrome.
[49]
MGMT Gene Silencing and Benefit from Temozolomide in ...
Mar 10, 2005 · Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not ...
[50]
PI3K/AKT/mTOR signaling transduction pathway and targeted ...
Aug 18, 2023 · In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR ...
[51]
Wnt signaling in colorectal cancer: pathogenic role and therapeutic ...
Jul 14, 2022 · The Wnt/β-catenin signaling pathway is one of the main regulators of homeostasis and cancer stemness, and germ cell tumors, as the malignant ...
[52]
Symptoms of Cancer - NCI
May 16, 2019 · Symptoms of Cancer · Breast changes · Bladder changes · Bleeding or bruising · Bowel changes · Cough · Eating problems · Fatigue · Fever or night sweats ...
[53]
Breast Cancer Treatment
### Symptoms and Clinical Presentation of Primary Breast Cancer
[54]
Non-Small Cell Lung Cancer Treatment
### Symptoms of Primary Lung Cancer
[55]
Pancreatic Cancer Treatment
### Symptoms of Primary Pancreatic Cancer
[56]
Colon Cancer Treatment
### Symptoms and Progression of Primary Colorectal Cancer, Including Obstruction
[57]
Paraneoplastic Syndromes - StatPearls - NCBI Bookshelf - NIH
Paraneoplastic syndromes are rare disorders with complex systemic clinical manifestations from an occult malignancy causing an altered immune system.
[58]
Cancer - Symptoms and causes - Mayo Clinic
Nov 19, 2024 · Cancer that involves the brain can cause headaches and stroke-like signs and symptoms, such as weakness on one side of your body. Unusual immune ...
[59]
Recommendation: Prostate Cancer: Screening - uspstf
May 8, 2018 · Men with a positive PSA test result may undergo a transrectal ultrasound-guided core-needle biopsy of the prostate to diagnose prostate cancer.
[60]
Global cancer statistics 2022: GLOBOCAN estimates of incidence ...
Apr 4, 2024 · There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths ...
[61]
Cancer statistics, 2025 - American Cancer Society Journals - Wiley
Jan 16, 2025 · In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued ...
[62]
[PDF] 2025 Cancer Facts and Figures - American Cancer Society
New cases and deaths: In the US in 2025, there will be an estimated 316,950 new cases of invasive breast cancer diagnosed in women and 2,800 cases in men, with ...
[63]
Global cancer burden growing, amidst mounting need for services
Feb 1, 2024 · Over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022.
[64]
Tests and Procedures Used to Diagnose Cancer - NCI
Jan 17, 2023 · Imaging tests create pictures of areas inside your body that help the doctor see whether a tumor is present. These pictures can be made in ...Diagnosis and Staging · Cancer Staging · Pathology Reports · Tumor Markers
[65]
Standard clinical approaches and emerging modalities for ... - PMC
Magnetic resonance imaging (MRI) is the modality of choice for diagnosis and assessment of treatment response due to its wide availability, and superior soft ...
[66]
The role of diagnostic imaging in the primary testicular cancer
Multimodality imaging is used for initial staging, with ultrasound and computed tomography (CT) most commonly utilized. Diagnostic imaging is also important in ...
[67]
Impact of Primary Tumor Diameter and SUV max on Pathological ...
Dec 17, 2024 · This indicates that lesions or tissues with an SUVmax >2.5 are more likely to be cancerous than those with an SUVmax 2.5. However, some benign ...
[68]
Mammography screening reduces rates of advanced and fatal ...
May 11, 2020 · Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 ...
[69]
Colorectal Cancer Guideline | How Often to Have Screening Tests
Jan 29, 2024 · The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45.
[70]
Recommendation: Colorectal Cancer: Screening - uspstf
May 18, 2021 · The USPSTF expanded the recommended ages for colorectal cancer screening to 45 to 75 years (previously, it was 50 to 75 years). The USPSTF ...Screening · Screening, 1996 · Final recommendation statement · Modeling Study
[71]
Enhanced MRI brain tumor detection using deep learning in ... - Nature
Aug 11, 2025 · Recent innovations in medical imaging have markedly improved brain tumor identification, surpassing conventional diagnostic approaches that ...
[72]
Liquid Biopsy Approaches for Cancer Characterization, Residual ...
Apr 30, 2025 · In the past decade, advances in circulating tumor DNA (ctDNA) analyses are propelling liquid biopsies toward widespread clinical integration.
[73]
Advances in AI — October 2025 | Diagnostic Imaging
Oct 25, 2025 · A new meta-analysis found that MRI-based deep learning provided pooled sensitivity, specificity and an AUC of 89 percent, 85 percent and 93 ...
[74]
Limitations of Mammograms - American Cancer Society
Jan 14, 2022 · Mammograms have their limits. For example, they aren't 100% accurate in showing if a woman has breast cancer. They can miss some cancers.
[75]
False-Positive and False-Negative Contrast-enhanced Mammograms
Nov 30, 2023 · The authors review various causes of false-positive and false-negative contrast-enhanced mammograms and discuss strategies to reduce these diagnostic errors.Missing: exposure | Show results with:exposure
[76]
Projected Lifetime Cancer Risks From Current Computed ...
However, there is also evidence that CT damages DNA in adults. Radiation-induced cancer risks from CT examinations vary by radiation dose, which depends on the ...
[77]
Types of biopsy procedures used to diagnose cancer - Mayo Clinic
Biopsy: Types of biopsy procedures used to diagnose cancer · Needle biopsy · Needle biopsy · Needle biopsy · Endoscopic biopsy · Endoscopy · Endoscopy · Punch biopsy ...
[78]
What Is a Biopsy? Purpose & Results - Cleveland Clinic
Biopsy types include bone marrow biopsy, excisional biopsy, needle biopsy and sentinel node biopsy. What is a biopsy? A biopsy is one of the ways healthcare ...
[79]
Biopsy | MaineHealth
Biopsy Types ; Needle biopsy: May be a core biopsy or fine need aspiration; ; Excisional biopsy: The entire tumor is removed through a cut in the skin.
[80]
Tests Used on Biopsy and Cytology Samples to Diagnose and ...
Aug 1, 2023 · Histochemical stains. These tests use different chemical dyes that are attracted to certain substances found in some types of cancer cells.
[81]
Special Stains in Histology - WebPath
PAS (peroidic acid-Schiff) - Stains glycogen as well as mucins, but tissue can be pre-digested with diastase to remove glycogen. Mucicarmine - Very specific for ...
[82]
Breast Cancer HER2 Status | What is HER2 Status?
Jan 29, 2025 · If the IHC is 2+ and the FISH is positive OR IHC is 3+, the cancer is HER2-positive. These cancers are usually treated with drugs that target ...Missing: primary | Show results with:primary<|control11|><|separator|>
[83]
Gleason Score: Grading System for Prostate Cancer - Cleveland Clinic
Gleason scores range from 6 (low-grade cancer) to 10 (high-grade cancer). Low grade prostate cancer grows more slowly than high-grade cancer and is less likely ...
[84]
Comparing Cancer Cells With Normal Cells - Breast Cancer Grades
Aug 25, 2023 · Breast Cancer Grades (Nottingham Grade) ... The Nottingham grade tells you how the cancer cells look and are growing compared with normal cells.Missing: primary | Show results with:primary
[85]
The impact of biopsy sampling errors and the quality of surgical ...
Such errors are reported to occur in up to 41% of cases, with a reported higher incidence in pelvic tumors.
[86]
Quality Measures for Multidisciplinary Tumor Boards and Their Role ...
Pathologic diagnosis. Evaluation for morphology and immunohistochemistry. Molecular tumor profiling (NGS). Mediastinal staging. Imaging CT/PET. Brain Imaging.
[87]
Breast Cancer Treatment (PDQ®) - NCI
Apr 25, 2025 · Large primary tumors. Very close or positive deep margins of resection of the primary tumor. In this high-risk group, radiation therapy can ...Missing: R0 | Show results with:R0
[88]
Pancreatic Cancer Treatment (PDQ®) - NCI
Feb 12, 2025 · Whipple procedure (pancreaticoduodenal resection). Total pancreatectomy when necessary for adequate margins. Distal pancreatectomy for tumors of ...
[89]
[PDF] NCCN Guidelines for Patients: Ductal Carcinoma In Situ
A clear or negative margin (R0) is when no cancer cells are found in the tissue around the edge of the tumor. In a positive margin, cancer cells are found in ...Missing: curative intent
[90]
Rectal Cancer after Prostate Radiation - NIH
Apr 9, 2023 · Ionizing radiation acts by targeting DNA, resulting in direct double-strand breaks, and by the production of free radicals, which indirectly ...
[91]
Cervical Cancer Treatment (PDQ®) - NCI
May 13, 2025 · External-beam pelvic radiation therapy combined with two or more intracavitary brachytherapy applications is appropriate therapy for patients ...
[92]
Ablative therapies for small renal tumors - PMC
The most commonly used ablative techniques in urology are cryoablation and radiofrequency ablation (RFA).
[93]
Renal Cell Cancer Treatment (PDQ®)–Patient Version
May 12, 2025 · Cryosurgery uses an instrument to freeze and destroy abnormal tissue. This type of treatment is also called cryotherapy. Learn more about ...
[94]
Non-cancer effects after proton beam therapy for pediatric tumors
May 30, 2025 · Proton beam therapy is considered as safer and more effective than traditional photon therapy because this type of modality offers precise ...
[95]
Systematic Review and Meta-Analysis of Proton Beam Therapy ...
Jun 29, 2025 · Proton beam therapy (PBT) has emerged as an alternative that offers precise radiation delivery that spares adjacent normal tissues [7]. This ...
[96]
CMF revisited in the 21st century - Annals of Oncology
Classical CMF (combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil) has been a milestone in the adjuvant treatment of women with ...
[97]
Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer
Among the chemotherapy agents that are associated with greater survival are older drugs such as the alkylating agents (mainly cyclophosphamide), the ...
[98]
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET ...
Anti-metabolites, such as 5-FU or CAP are often used in tumors of the gastrointestinal tract in combination with other drugs, such as oxaliplatin and irinotecan ...
[99]
5-Fluorouracil (5-FU) resistance and the new strategy to enhance ...
It is reported that the response rate of 5-FU based first-line chemotherapy in advanced CRC cases is still only 10–15 %. But when 5-FU is combined with other ...
[100]
Imatinib: A Breakthrough of Targeted Therapy in Cancer - PMC
Imatinib has revolutionized the therapy of malignancies that are addicted to one of its target kinases, c-ABL, c-KIT, and PDGFR.Missing: immunotherapy MSI- ORR
[101]
PD-L1 Expression as a Predictive Biomarker in Cancer ...
Emerging data suggest that patients whose tumors overexpress PD-L1 by IHC have improved clinical outcomes with anti-PD-1–directed therapy.
[102]
Prognostic Value of Breast Cancer Subtypes, Ki‐67 Proliferation ...
Dec 13, 2012 · Our results showed that patients with stage IIB through stage IV breast carcinomas were 2.1–16 times more likely to die than patients with ...
[103]
Prognostic Importance of Ki-67 in Breast Cancer and Its ... - NIH
We established three categories based on Ki-67 level: low (<10%), intermediate (10–25%) and high (>25%) as some authors specified 'low proliferative activity' ...
[104]
The prognostic and predictive potential of Ki-67 in triple-negative ...
Jan 14, 2020 · Thus, Ki-67 cutoff at 30% had early independent prognostic and predictive potential for OS and DFS in TNBCs, and Ki-67 > 30% was significantly ...
[105]
CAR-T cell therapy for cancer: current challenges and future directions
Jul 4, 2025 · This review offers an overview of the current development of CAR-T cell therapies for both hematologic and solid tumors, while examining the ...
[106]
ACS Annual Report: Cancer Mortality Continues to Drop Despite ...
Jan 16, 2025 · The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting approximately 4.5 million deaths.
[107]
Comparison of different prostatic markers in lymph node and distant ...
Jun 13, 2014 · PSAP expression decreases significantly from benign prostatic tissue to primary prostate cancer, lymph node metastases, and distant metastases ...
[108]
Metastatic tumor cells – genotypes and phenotypes - PMC - NIH
On the one hand, metastatic cells inherit critical driver mutations from their parental tumors allowing the persistence of tumorigenic ability. On the other ...
[109]
Pan-cancer whole-genome comparison of primary and metastatic ...
May 10, 2023 · Metastatic tumours in general have a lower intratumour heterogeneity and a conserved karyotype, displaying only a modest increase in mutations, ...
[110]
Genetic differences between primary and metastatic cancer - Nature
Sep 29, 2023 · Meanwhile, the researchers observed that, compared with primary cancers, metastatic cancers only have a moderate increase in tumor mutation ...
[111]
Tumor microenvironment differences between primary ... - PMC - NIH
Jan 3, 2020 · Metastatic spread is a process wherein cancer cells move from their primary location to a distant site, colonizing and growing in a new location ...
[112]
The seed and soil hypothesis revisited - the role of tumor-stroma ...
However, data derived from spontaneous tumor models of melanoma metastasis that require successful completion of each step of the metastatic process showed that ...
[113]
Comparison of Tumor Microenvironments Between Primary ... - NIH
In this study, we have revealed that brain metastases have fewer TILs, such as CD4+ T-cells and CD8+ T-cells, when compared with the primary lesion from the ...
[114]
Differences in Tumor Immune Microenvironment in Metastatic Sites ...
Mar 18, 2021 · The TIMEs of metastatic lymph nodes had fewer macrophages than those of primary tumors (Figures 4B,C). There were more B-cells and T-cells in ...
[115]
Growth rates of primary and metastatic lesions of renal cell carcinoma
The growth rates of primary and metastatic lesions of RCC varied. They ranged from 0.10 to 1.35 cm/year for primary lesions and from 0.08 to 7.87 cm/year for ...
[116]
Vascular mimicry: Triggers, molecular interactions and in vivo models
... primary tumors, metastasis and vascular mimicry. 5.2. EGFR. The epidermal ... metastatic tumors, as well as to prevent cancer recurrence, invasion and metastasis.
[117]
Primary tumor and metastasis—sectioning the different steps ... - NIH
Metastasis is a multistep procedure. It requires a change in adhesion of tumor cells for detachment from their neighboring cells.
[118]
Colorectal Cancer Stages and Survival Rate
Localized: The cancer hasn't spread outside the primary site. The five-year relative survival rate for localized colorectal cancer is 90.9 percent. Regional ...Colorectal Cancer Stages · Stages Of Colorectal Cancer · Stage 3 Colorectal CancerMissing: general | Show results with:general
[119]
Targeting metastatic cancer - PMC - NIH
Unlike primary tumors, which can often be cured using local surgery or radiation, metastasis is a systemic disease. Systemic approaches, including screening, ...
[120]
https://www.cancercenter.com/cancer-types/colorectal-cancer/stages
[121]
Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer
Results: We observed a tumor size reduction in 95% of cases, resulting in downstaging in 62.7%. The average tumor shrinkage was 49%. Women with a reduction in ...